PD26-08 LOW-GRADE UROTHELIAL CARCINOMA RECURS AT A TEMPO THAT NATURALLY ACCELERATES FROM ADAGIO TO ALLEGRO

Abstract

You have accessJournal of UrologyCME1 May 2022PD26-08 LOW-GRADE UROTHELIAL CARCINOMA RECURS AT A TEMPO THAT NATURALLY ACCELERATES FROM ADAGIO TO ALLEGRO Alex Sankin, Louise-Rae Cherrill, Rebecca H. Boucher, Maurice P. Zeegers, K. K. Cheng, Nicholas D. James, Mark Schoenberg, Ilir Agalliu, and Richard T. Bryan Alex SankinAlex Sankin More articles by this author , Louise-Rae CherrillLouise-Rae Cherrill More articles by this author , Rebecca H. BoucherRebecca H. Boucher More articles by this author , Maurice P. ZeegersMaurice P. Zeegers More articles by this author , K. K. ChengK. K. Cheng More articles by this author , Nicholas D. JamesNicholas D. James More articles by this author , Mark SchoenbergMark Schoenberg More articles by this author , Ilir AgalliuIlir Agalliu More articles by this author , and Richard T. BryanRichard T. Bryan More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000002574.08AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Patients with low grade urothelial carcinoma are at a lifetime risk of recurrence and often require multiple interventions including repeat transurethral resections and intravesical therapy. We present an exploratory analysis of the frequency of recurrence in patients with low grade intermediate-risk non-muscle invasive bladder cancer (NMIBC) from a comprehensive large-scale prospective cohort in the UK. METHODS: The Bladder Cancer Prognosis Programme (BCPP) is a prospective cohort of 1191 patients with newly-diagnosed bladder cancer who were recruited from 2005-2011 at 10 urological centers within the West Midlands, UK, and who remain under follow-up. Risk group was assigned according to European Association of Urology criteria. Time to first recurrence is defined as the time from registration to detection of first recurrence of bladder cancer; time between first recurrence and second recurrence is defined as the time from the detection of the first recurrence to the detection of the second recurrence, and so on for time between subsequent recurrences. All recurrence-free intervals are calculated using the Kaplan-Meier method. RESULTS: We identified 379 patients with G1/G2 pTa tumors classified as intermediate risk (Table 1). Median age was 70 and 284/379 (75%) were male. 53% of patients had at least one recurrence after 5 years of follow-up. 1-year recurrence-free survival (RFS) was 75%, 2-year RFS was 61%, 3-year RFS was 54%, and 4-year RFS was 50%. The median time to 1st, 2nd, 3rd, 4th, and 5th sequential recurrence was 49, 19, 12, 14, and 10 months, respectively (Figure 1). CONCLUSIONS: Over half of patients with low grade urothelial tumors are destined to recur. As tumors recur sequentially over time, the rate of recurrence appears to accelerate. The natural cadence of tumor recurrence may represent a kinetic biomarker that could inform both surveillance and intervention protocols. Source of Funding: Urogen Pharma © 2022 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 207Issue Supplement 5May 2022Page: e490 Advertisement Copyright & Permissions© 2022 by American Urological Association Education and Research, Inc.MetricsAuthor Information Alex Sankin More articles by this author Louise-Rae Cherrill More articles by this author Rebecca H. Boucher More articles by this author Maurice P. Zeegers More articles by this author K. K. Cheng More articles by this author Nicholas D. James More articles by this author Mark Schoenberg More articles by this author Ilir Agalliu More articles by this author Richard T. Bryan More articles by this author Expand All Advertisement PDF DownloadLoading ...